| Tue, Jul 28, 2009 |
|
Lotus Restructuring Efforts & Long-term Outlook
Lotus Pharmaceuticals, Inc. (LTUS) may not be as popular as Teva Pharmaceuticals (TEVA) or Johnson & Johnson (JNJ), but this profitable under-the-radar pharmaceutical company is profiting handsomely in China’s growing market.
Lotus Pharmaceuticals, Inc. [[LTUS.OB]], a China-based drug manufacturer and distributor, is trading at just two times earnings despite posting incredibly strong growth rates last quarter. [...]
-
OTC Investor :: The ...
|
| Fri, Jul 24, 2009 |
|
|
Top 5 OTC Stocks for Today
Advanced Life Sciences Holdings, Inc. (ADLS), NeoGenomics, Inc. (NGNM), Lotus Pharmaceuticals, Inc. (LTUS), SinoHub Inc. (SIHI), and Genta Incorporated (GETA) were among today’s top OTC movers.
Advanced Life Sciences Holdings, Inc. [[ADLS.OB]], a biopharmaceutical company focused on infectious diseases, saw its shares jump more than 20 percent amid speculation that the government will put pressure on [...]
-
OTC Investor :: The ...
|
| Sun, Nov 23, 2008 |
|
|
The Week In Review: Biopharma News Back In The Forefront
ChinaBio® Accelerator will hold the ChinaBio® Partnering Forum on June 3 and 4, 2009 in Shanghai; Chiral Quest raised $13 million in a Series B financing from China-based venture capitalists; GSK and Shenzhen Neptunus Interlong will work towards a JV that develops flu vaccines; BMP Sunstone has acquired rights to the Runchang capsule, a liquid-filled hard capsule; Syneron Medical has established a JV to market its medical aesthetic devices in China; China Medical Technologies has developed two molecular diagnostic kits to detect EFGR abnormalities; big pharma continues to make investments in China; China Medical Technologies released positive Q2 results, Genesis Pharmaceuticals reported that Q1 revenues and earnings climbed significantly; Lotus Pharma said its Q3 net income climbed even though revenues dropped slightly; Sinovac Biotech reported that revenue and profits declined in Q3; and China Shenghuo Pharmareleased its Q3 [More...] |
| Tue, Nov 18, 2008 |
|
|
Lotus Increases Profit In Q3 While Revenues Drop
Lotus Pharmaceuticals announced that its Q3 net income climbed 45% to $3.2 million, even though revenues dropped slightly in the quarter to $16.6 million. The company earned 7 cents per share, fully diluted, bringing its nine-month eps total to 16 cents. Lotus reported that its revenue mix, when compared to the year-ago quarter, were the reason that earnings increased while revenue stayed flat. More details... Stock Symbol: (OTCBB: LTUS) [More...] |
| Sat, Aug 23, 2008 |
|
|
The Week in Review: Earnings and Development
Earnings reports for China biomedical companies continued to be released at a slower pace over the past five days. Lotus Pharma announced its revenues climbed an admirable 51% but net income dropped 27%; Sinobiomed emphasized its pipeline rather than its revenues, which are falling; and China Shenghuo Pharma said it will have to restate its reports because of irregularities; Smith & Nephew will expanding two China manufacturing facilities; CRO Venturepharm Labs purchased 44% of the US CRO, Commonwealth Biotechnologies; and MicuRx Pharma picked its first preclinical development candidate, a next-generation antibiotic. More details... Stock Symbols: (OTCBB: LTUS) (OTCBB: SOBM) (AMEX: KUN) (NYSE: SNN) (HKEX: 8225) (NSDQ: CBTE) [More...] |
|
More Blogs
|
